GXGX
Celularity Inc. [GXGX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
GXGX Stock Summary
In the News
GXGX Financial details
Company Rating
Neutral
Market Cap
1.48B
Income
-181.41M
Revenue
14.79M
Book val./share
1.61
Cash/share
0.01
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
-
P/E
-0.89
Forward P/E
-
PEG
0.28
P/S
-
P/B
400.77
P/C
1020
P/FCF
-41.02
Quick Ratio
85.67
Current Ratio
0.11
Debt / Equity
2.02
LT Debt / Equity
0.86
-
-
EPS (TTM)
-10.18
EPS next Y
-
EPS next Q
-
EPS this Y
-106.76%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
28.86%
EPS Q/Q
83.09%
-
-
-
-
SMA20
100%
SMA50
-
SMA100
-
Inst Own
0.01%
Inst Trans
0%
ROA
-769%
ROE
-2%
ROC
-14.61%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
8.07-12.58
52W High
-15%
52W Low
+27.5%
RSI
30
Rel Volume
27.85
Avg Volume
621.77K
Volume
17.32M
Perf Week
1297.07%
Perf Month
972.22%
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
-
-
-
Volatility
3.31%, 1.67%
Prev Close
1350.31%
Price
10.2
Change
1278.38%
GXGX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 6.11 | 7.75 | 3.18 | 1.28 | |
| Net income per share | 0 | 1.7 | -113.06 | -14.93 | 1.01 | |
| Operating cash flow per share | 0 | -0.32 | -34.31 | -16.42 | -9.85 | |
| Free cash flow per share | 0 | -9.44 | -49.42 | -17.34 | -10.23 | |
| Cash per share | 0 | 0.26 | 29.49 | 5.55 | 1 | |
| Book value per share | 0 | 76.08 | -288.52 | 14.83 | 14.22 | |
| Tangible book value per share | 0 | -39.04 | -423.55 | -21.93 | -2.99 | |
| Share holders equity per share | 0 | 76.08 | -288.52 | 14.83 | 14.22 | |
| Interest debt per share | 0 | -1.08 | 17.92 | 5.12 | -7.09 | |
| Market cap | 0 | 344.47M | 202.6M | 343.33M | 180.48M | |
| Enterprise value | 125.29K | 343.55M | 178.93M | 337.23M | 232.1M | |
| P/E ratio | 0 | 58.6 | -0.97 | -3.43 | 12.72 | |
| Price to sales ratio | 0 | 16.29 | 14.19 | 16.09 | 10.04 | |
| POCF ratio | 0 | -313.77 | -3.21 | -3.12 | -1.31 | |
| PFCF ratio | 0 | -10.54 | -2.23 | -2.95 | -1.26 | |
| P/B Ratio | 0 | 1.31 | -0.38 | 3.45 | 0.91 | |
| PTB ratio | 0 | 1.31 | -0.38 | 3.45 | 0.91 | |
| EV to sales | 0 | 16.25 | 12.53 | 15.81 | 12.91 | |
| Enterprise value over EBITDA | 0 | -204.07 | -2.73 | -3.48 | -1.64 | |
| EV to operating cash flow | 0 | -312.94 | -2.83 | -3.06 | -1.68 | |
| EV to free cash flow | 0 | -10.51 | -1.97 | -2.9 | -1.62 | |
| Earnings yield | 0 | 0.02 | -1.03 | -0.29 | 0.08 | |
| Free cash flow yield | 0 | -0.09 | -0.45 | -0.34 | -0.79 | |
| Debt to equity | 0 | 0 | -0.06 | 0.31 | 0.33 | |
| Debt to assets | 0 | 0 | 0.07 | 0.08 | 0.16 | |
| Net debt to EBITDA | 0 | 0.54 | 0.36 | 0.06 | -0.37 | |
| Current ratio | 0.16 | 4.4 | 2.7 | 1.42 | 0.54 | |
| Interest coverage | 0 | 0.45 | -33.17 | -46.68 | 0.16 | |
| Income quality | 0 | -0.19 | 0.3 | 1.1 | -9.72 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0.22 | |
| Payout ratio | 0 | 0 | 0 | 0 | 2.75 | |
| Sales general and administrative to revenue | 0 | 0.03 | 2.14 | 3.33 | 3.66 | |
| Research and developement to revenue | 0 | 2.18 | 3.69 | 4.14 | 4.36 | |
| Intangibles to total assets | 0 | 1.37 | 0.58 | 0.6 | 0.6 | |
| Capex to operating cash flow | 0 | 28.76 | 0.44 | 0.06 | 0.04 | |
| Capex to revenue | 0 | -1.49 | -1.95 | -0.29 | -0.29 | |
| Capex to depreciation | 0 | -5.1 | -3.41 | -0.7 | -0.55 | |
| Stock based compensation to revenue | 0 | 0.17 | 0.31 | 1.88 | 0.88 | |
| Graham number | 0 | 53.92 | 856.72 | 70.57 | 18.01 | |
| ROIC | 0 | -0.01 | 0.16 | -0.92 | -0.09 | |
| Return on tangible assets | 0 | -0.05 | -1.14 | -0.6 | 0.09 | |
| Graham Net | 0 | -6.75 | -489.34 | -40.08 | -12.89 | |
| Working capital | -125.85K | 780.06K | 45.48M | 11.02M | -28.59M | |
| Tangible asset value | 23.9K | -135.14M | -780.08M | -147.07M | -41.79M | |
| Net current asset value | -125.85K | -27.2M | -890.25M | -277.47M | -168.66M | |
| Invested capital | 0 | 0 | -0.06 | 0.31 | 0.33 | |
| Average receivables | 0 | 1.54M | 4.81M | 5.89M | 6.1M | |
| Average payables | 0 | 1.85M | 4.54M | 7.35M | 7.56M | |
| Average inventory | 0 | 1.62M | 3.54M | 6.7M | 7.43M | |
| Days sales outstanding | 0 | 53.13 | 167.44 | 89.53 | 141.45 | |
| Days payables outstanding | 0 | 213.03 | 398.89 | 352.3 | 107.84 | |
| Days of inventory on hand | 0 | 186.54 | 284.92 | 361.07 | 98.52 | |
| Receivables turnover | 0 | 6.87 | 2.18 | 4.08 | 2.58 | |
| Payables turnover | 0 | 1.71 | 0.92 | 1.04 | 3.38 | |
| Inventory turnover | 0 | 1.96 | 1.28 | 1.01 | 3.7 | |
| ROE | 0 | 0.02 | 0.39 | -1.01 | 0.07 | |
| Capex per share | 0 | -9.12 | -15.11 | -0.93 | -0.37 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.03 | 0.28 | 0.25 | 0.17 | 0.2 | |
| Net income per share | 0.03 | 1.64 | -4.12 | -2.72 | -4.98 | |
| Operating cash flow per share | -0.25 | -1.99 | -0.97 | -0.62 | -0.44 | |
| Free cash flow per share | -0.26 | -2.04 | -1.17 | -0.63 | -0.45 | |
| Cash per share | 0.28 | 0.94 | 0.55 | 0.17 | 0.01 | |
| Book value per share | 1.09 | 13.36 | 10.02 | 6.71 | 1.61 | |
| Tangible book value per share | -0.54 | -2.81 | -3.53 | 0.93 | 0.6 | |
| Share holders equity per share | 1.09 | 13.36 | 10.02 | 6.71 | 1.61 | |
| Interest debt per share | 0.38 | 0.39 | 4.12 | 3.57 | 3.29 | |
| Market cap | 3.48B | 192.11M | 96.33M | 94.11M | 41.81M | |
| Enterprise value | 3.5B | 243.73M | 151.53M | 152.97M | 102.61M | |
| P/E ratio | 181.16 | 1.97 | -0.38 | -0.49 | -0.11 | |
| Price to sales ratio | 841.02 | 46.53 | 24.48 | 32.03 | 11.04 | |
| POCF ratio | -92.2 | -6.49 | -6.42 | -8.53 | -5.02 | |
| PFCF ratio | -88.53 | -6.33 | -5.29 | -8.51 | -4.89 | |
| P/B Ratio | 21.17 | 0.97 | 0.62 | 0.79 | 1.38 | |
| PTB ratio | 21.17 | 0.97 | 0.62 | 0.79 | 1.38 | |
| EV to sales | 846.95 | 59.03 | 38.51 | 52.07 | 27.1 | |
| Enterprise value over EBITDA | -98.93 | -7.42 | -2.89 | -6.95 | -7.87 | |
| EV to operating cash flow | -92.85 | -8.24 | -10.11 | -13.87 | -12.33 | |
| EV to free cash flow | -89.15 | -8.03 | -8.32 | -13.83 | -12 | |
| Earnings yield | 0 | 0.13 | -0.66 | -0.51 | -2.25 | |
| Free cash flow yield | -0.01 | -0.16 | -0.19 | -0.12 | -0.2 | |
| Debt to equity | 0.41 | 0.33 | 0.41 | 0.52 | 2.02 | |
| Debt to assets | 0.15 | 0.16 | 0.18 | 0.25 | 0.39 | |
| Net debt to EBITDA | -0.69 | -1.57 | -1.05 | -2.68 | -4.66 | |
| Current ratio | 0.91 | 0.54 | 0.38 | 0.28 | 0.19 | |
| Interest coverage | 0.54 | -0.29 | -230.58 | -38.47 | -102.22 | |
| Income quality | -7.86 | -1.21 | 0.23 | 0.23 | 0.09 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 4.58 | 0 | 0 | 0 | |
| Research and developement to revenue | 4.92 | 2.66 | 4.31 | 2.93 | 1.37 | |
| Intangibles to total assets | 0.56 | 0.6 | 0.58 | 0.41 | 0.12 | |
| Capex to operating cash flow | 0.04 | 0.03 | 0.21 | 0 | 0.03 | |
| Capex to revenue | -0.38 | -0.19 | -0.82 | -0.01 | -0.06 | |
| Capex to depreciation | -0.65 | -0.32 | -1.36 | -0.01 | -0.1 | |
| Stock based compensation to revenue | 1.09 | 1.06 | 1.01 | 1.31 | 0.95 | |
| Graham number | 0.88 | 22.2 | 30.47 | 20.25 | 13.42 | |
| ROIC | -0.02 | 0.06 | -0.26 | -0.19 | -0.86 | |
| Return on tangible assets | 0.02 | 0.15 | -0.42 | -0.33 | -0.68 | |
| Graham Net | -1.47 | -12.11 | -12.33 | -6.7 | -6.35 | |
| Working capital | -6.12M | -28.59M | -41.45M | -46.94M | -68.13M | |
| Tangible asset value | -80.62M | -41.79M | -54.89M | 16.33M | 11.35M | |
| Net current asset value | -209.78M | -168.66M | -181.78M | -109.88M | -110.45M | |
| Invested capital | 0.41 | 0.33 | 0.41 | 0.52 | 2.02 | |
| Average receivables | 7.5M | 7.67M | 6.07M | 5.02M | 5.54M | |
| Average payables | 9.72M | 7.51M | 7.28M | 10.6M | 12.69M | |
| Average inventory | 14.95M | 5.27M | 5.4M | 5.61M | 5.34M | |
| Days sales outstanding | 182.22 | 151.84 | 118.13 | 149.61 | 147.05 | |
| Days payables outstanding | 114.99 | 99.66 | 30.69 | 1.07K | 323.1 | |
| Days of inventory on hand | 65.37 | 91.05 | 19.22 | 494.18 | 123.28 | |
| Receivables turnover | 0.49 | 0.59 | 0.76 | 0.6 | 0.61 | |
| Payables turnover | 0.78 | 0.9 | 2.93 | 0.08 | 0.28 | |
| Inventory turnover | 1.38 | 0.99 | 4.68 | 0.18 | 0.73 | |
| ROE | 0.03 | 0.12 | -0.41 | -0.4 | -3.1 | |
| Capex per share | -0.01 | -0.05 | -0.21 | 0 | -0.01 |
GXGX Frequently Asked Questions
What is Celularity Inc. stock symbol ?
Celularity Inc. is a US stock , located in New york city of New york and trading under the symbol GXGX
What is Celularity Inc. stock quote today ?
Celularity Inc. stock price is $10.2 today.
Is Celularity Inc. stock public?
Yes, Celularity Inc. is a publicly traded company.
Company Profile
- Volume Average 621.77K
- Market Capitalization 1.48B
- CEO Mr. Jay R. Bloom
- Headquarters New York City,NEW YORK,US
- IPO Date 2019-05-21
-
Website
http://celularity.com 
GX Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company is not engaged in any business operations and it has not generated any revenue.
